X

Clinical Trials

Contact Us

Lung Cancer

2018-01 (MBMC only) (temporarily closed)

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors


NCI 10231 (MBMC only)

NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study


EA5163

A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis


S1900A (Temporarily Closed 7/16/20)

A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)


LUNGMAP

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)


EA5162 (suspended effective 7/9/19)

Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR


NRG LU002 (NCT03137771)

Maintenance systemic therapy versus consolidative sterotactic body radiation therapy (SBRT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer: A randomized phases II/III trial.


ECOG E4512 (NCT02201992) – Must have Consented to ALCHEMIST A151216 Trial

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein


A081105 (NCT02193282) – Must have Consented to ALCHEMIST A151216 Trial

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)


A151216 (NCT02194738) ALCHEMIST (suspended for pts w/squamous histology effective 8/26/19)

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)